Capital Fund Management S.A. Alkermes Plc. Transaction History

Capital Fund Management S.A.

$36 Billion
Q3 2025

A detailed history of Capital Fund Management S.A. transactions in Alkermes Plc. stock. As of the latest transaction made, Capital Fund Management S.A. holds 120,959 shares of ALKS stock, worth $3.51 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

120,959

Previous 39,929 202.94%

Holding current value

$3.51 Million

Previous $1.14 Million 217.69%

% of portfolio

0.01%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$26.13 - $30.46 $2.12 Million - $2.47 Million	81,030 Added 202.94%	120,959 $3.63 Million
Q2 2025 Aug 13, 2025	BUY	$26.59 - $32.65 $1.06 Million - $1.3 Million	39,929 New	39,929 $1.14 Million
Q4 2024 Feb 13, 2025	SELL	$25.7 - $31.46 $2.97 Million - $3.63 Million	-115,471 Reduced 41.38%	163,581 $4.7 Million
Q3 2024 Nov 13, 2024	BUY	$23.01 - $28.55 $485,395 - $602,262	21,095 Added 8.18%	279,052 $7.81 Million
Q2 2024 Aug 13, 2024	BUY	$23.21 - $27.24 $2.64 Million - $3.1 Million	113,660 Added 78.77%	257,957 $6.22 Million

Q1 2024 May 15, 2024	BUY	$26.4 - $32.56 $3.19 Million - $3.93 Million	120,816 Added 514.53%	144,297 $3.91 Million
Q4 2023 Feb 14, 2024	SELL	$23.37 - $28.68 $2.76 Million - $3.39 Million	-118,176 Reduced 83.42%	23,481 $651,000
Q3 2023 Nov 14, 2023	SELL	$27.17 - $31.97 $650,015 - $764,850	-23,924 Reduced 14.45%	141,657 $3.97 Million
Q2 2023 Aug 14, 2023	SELL	$28.34 - $33.63 $2.14 Million - $2.54 Million	-75,467 Reduced 31.31%	165,581 $5.18 Million
Q1 2023 May 15, 2023	SELL	$25.31 - $29.02 $3.41 Million - $3.91 Million	-134,708 Reduced 35.85%	241,048 $6.8 Million
Q4 2022 Feb 13, 2023	BUY	$21.94 - $26.24 $2.37 Million - $2.84 Million	108,103 Added 40.39%	375,756 $9.82 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $2.03 Million - $2.95 Million	92,495 Added 52.81%	267,653 $5.98 Billion
Q2 2022 Aug 12, 2022	BUY	$26.4 - $30.54 $2.77 Million - $3.21 Million	104,956 Added 149.51%	175,158 $5.22 Million
Q1 2022 May 12, 2022	BUY	$23.07 - $27.99 $1.62 Million - $1.96 Million	70,202 New	70,202 $1.85 Million
Q4 2020 Feb 12, 2021	SELL	$15.39 - $22.1 $280,390 - $402,639	-18,219 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$16.16 - $20.66 $297,958 - $380,929	-18,438 Reduced 50.3%	18,219 $301,000
Q2 2020 Aug 13, 2020	BUY	$13.31 - $19.41 $58,417 - $85,190	4,389 Added 13.6%	36,657 $711,000
Q1 2020 May 13, 2020	SELL	$13.06 - $21.24 $211,989 - $344,767	-16,232 Reduced 33.47%	32,268 $465,000
Q4 2019 Feb 13, 2020	BUY	$17.29 - $21.74 $838,565 - $1.05 Million	48,500 New	48,500 $989,000
Q3 2019 Nov 13, 2019	SELL	$19.51 - $24.28 $1.49 Million - $1.85 Million	-76,233 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$21.47 - $37.33 $2.09 Million - $3.64 Million	-97,400 Reduced 56.1%	76,233 $1.72 Million
Q1 2019 May 13, 2019	SELL	$28.4 - $36.49 $235,720 - $302,867	-8,300 Reduced 4.56%	173,633 $6.34 Million
Q4 2018 Feb 13, 2019	SELL	$27.94 - $44.61 $1.29 Million - $2.07 Million	-46,300 Reduced 20.29%	181,933 $5.37 Million
Q3 2018 Nov 14, 2018	BUY	$38.6 - $46.12 $4.91 Million - $5.87 Million	127,195 Added 125.89%	228,233 $9.69 Million
Q2 2018 Aug 14, 2018	BUY	$40.56 - $51.36 $4.1 Million - $5.19 Million	101,038 New	101,038 $4.16 Million
Q1 2018 May 15, 2018	SELL	$53.61 - $67.26 $2.54 Million - $3.19 Million	-47,409 Closed	0 $0
Q4 2017 Feb 09, 2018	SELL	$47.69 - $55.39 $1.99 Million - $2.31 Million	-41,700 Reduced 46.8%	47,409 $2.6 Million
Q3 2017 Nov 13, 2017	BUY	$49.16 - $54.45 $4.38 Million - $4.85 Million	89,109	89,109 $4.53 Million

Others Institutions Holding ALKS

# of Institutions

402

Shares Held

176M

Call Options Held

901K

Put Options Held

400K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.77B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Capital Fund Management S.A. with notifications on news.

Account

Capital Fund Management S.A. Alkermes Plc. Transaction History